Psychedelic Clinical Trials
Find clinical trials studying psilocybin, MDMA, ketamine and other psychedelics. Many trials are actively recruiting participants who haven't found relief from conventional treatments.
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Definium Therapeutics US, Inc.
Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression
Stanford University
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Icahn School of Medicine at Mount Sinai
Psilocybin for Treatment-Resistant Depression
University of Colorado, Denver
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
COMPASS Pathways
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
COMPASS Pathways
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
COMPASS Pathways
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
Eleusis Therapeutics
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
Ohio State University
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
Johns Hopkins University
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Sheppard Pratt Health System
Opiate Suicide Study in Patients With Major Depression
Stanford University
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
Mayo Clinic
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Yale University
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression
Centre Hospitalier Universitaire de Nīmes
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
Brian Barnett
Low-Income Group Psilocybin Assisted Therapy for Depression
Matthew Hicks
(GluEsk) Glutamate and Esketamine
University of Oxford
Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Psilocybin in Alcohol Use Disorder With Comorbid Depression
Centre Hospitalier Universitaire de Nīmes
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
University of Chicago
KET-RO Plus RO DBT for Treatment Resistant Depression
Washington University School of Medicine
Microdosing Psychedelics to Improve Mood
Rotem Petranker
Psilocybin-assisted CBT for Depression
University of California, Los Angeles
Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression
Medical University of Gdansk
IM and IV SPL026 Drug Product in Healthy Participants
Small Pharma Ltd
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout
University of Utah
SPL026 With or Without SSRIs in Participants With MDD
Small Pharma Ltd
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
Maimonides Medical Center
Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression
Joshua Rosenblat
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
Cybin IRL Limited
Anhedonia, Development, and Emotions: Phenotyping and Therapeutics
Erika Forbes
Ketamine for Treatment-Resistant Bipolar Disorder
Joshua Rosenblat
Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets
University of Texas Southwestern Medical Center
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Sheppard Pratt Health System
Frontline Clinician Psilocybin Study
University of Washington
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
Perception Neuroscience
Ketamine for the Treatment of Depression in Parkinson's Disease
Yale University
Psilocybin for Treatment-Resistant Depression
Brain and Cognition Discovery Foundation
Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)
Centre for Addiction and Mental Health
Synaptic Imaging and Network Activity in Treatment Resistant Depression
King's College London
Ketamine As an Adjunctive Therapy for Major Depression (2)
University of Dublin, Trinity College
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
Joshua Woolley, MD, PhD
SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
Small Pharma Ltd
Pharmacogenetics Associated With IV Ketamine
Brain and Cognition Discovery Foundation
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
National Institute of Mental Health (NIMH)
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density
Section for Affective Disorders; Northern Stockholm Psychiatry
Browse by Condition
View all conditions →How to Join a Clinical Trial
Clinical trials are research studies that test new treatments. Participating can give you access to cutting-edge therapies while contributing to medical science. Each trial has specific eligibility criteria based on the research goals.
1. Review
Read the trial details, eligibility criteria, and what participation involves.
2. Contact
Reach out to the study team using the contact information provided.
3. Screen
Complete the screening process to determine if you're eligible.